Strontium for Health & Longevity - Quick Reference Sheet

Strontium for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Strontium is a mineral used as the prescription salt ranelate (withdrawn) and as dietary supplements such as citrate for fracture prevention in fragile bone. In older women with osteoporosis, ranelate was tied to fewer spine fractures and fewer other fractures. Clots were more common and the heart-attack picture is unsettled. Supplement salts lack a fracture trial. Density scans include an X-ray artifact. This concerns fractures and mobility, not slowing aging. (Full Review)

Protocol

Trial regimen, ranelate
2 g orally once daily
About 680 mg elemental; product withdrawn
Supplement regimen, citrate
About 680 mg elemental once daily
Fracture efficacy is unproven
Time of day
Bedtime
At least two hours after the last calcium-containing meal
Time to effect
Vertebral fractures
First year
Reduction already reported in the first year
Bone mineral density
Several years
Readings keep changing, including the X-ray artifact

Benefits

Contraindications
  • Current or past ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or uncontrolled hypertension
  • Prior venous thromboembolism, or current immobilization (prolonged bed rest)
  • Creatinine clearance below 30 mL/min
  • Prior DRESS-type reaction or hypersensitivity to strontium ranelate
  • Pregnancy and lactation
  • Children and adolescents
Key Interactions
  • Calcium (calcium carbonate, calcium citrate): separate by at least two hours
  • Dairy foods and calcium-fortified products: taken at bedtime, away from food
  • Antacids (aluminum hydroxide, magnesium hydroxide): separate by at least two hours
  • Tetracyclines (antibiotics; doxycycline, tetracycline): theoretical; separate by at least two hours
  • Quinolone antibiotics (ciprofloxacin, levofloxacin): not tested directly for strontium; separate by at least two hours
  • Oral bisphosphonates (alendronate, risedronate): combined effect unmeasured
  • Vitamin D: monitor; given with calcium, apart from the strontium dose

Risk & Side Effects

  • High: Venous Thromboembolism; Diarrhea and Nausea
  • Medium:
  • Low: Myocardial Infarction; Cardiovascular Death; Severe Drug Reaction With Rash; Memory Disturbance; Headache; Seizures; Disturbance in Consciousness; Dermatitis and Eczema
  • Speculative:

Monitoring

Marker Target Why
DXA, lumbar spine and hip No established target on strontium; track percent change from the person's own baseline Shows whether the reading is moving, including artifact
25-hydroxyvitamin D 40–60 ng/mL Background for the mineral effect seen in trials
Serum calcium 9.0–10.0 mg/dL, mid-normal Detects calcium imbalance while strontium is used
Creatinine clearance or eGFR At or above 90 mL/min Strontium is renally cleared
CTX No fixed target; a fall from the person's baseline is the signal used in trials Resorption context
P1NP No fixed target; direction versus the person's baseline Formation context

Cadence: Baseline DXA, serum calcium, kidney filtration, 25-hydroxyvitamin D, blood pressure, and history of heart disease, stroke, or clots. DXA at about 12 months, then every 12–24 months. Kidney filtration and calcium at about 3 months, then yearly. Turnover markers yearly if used. Earlier review for a new rash with fever, one-sided leg swelling, or chest pain.

Qualitative Assessment

  • New or worsening mid-back pain, loss of height, or a new fracture on imaging
  • Calf swelling, sudden shortness of breath, or chest pressure, as clot and heart signals
  • Loose stools, nausea, or a widespread rash with fever in the first months
  • Walking speed, ability to rise from a chair, and usual physical activity, as function rather than a scan number